While many companies have turned to remote working, leaving office spaces empty, science laboratories could be bucking that trend. A bearish market and a decrease in venture capital funding and investments may not majorly affect […]
Demand for neurology services in the U.K. is expected to register a CAGR of 5.0% over the next ten years. Demand for neurology services in Europe is expected to register a CAGR of 5.1% over […]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology […]
In the battle against Covid-19, vaccines came much earlier than therapeutics. A new research institution in Melbourne wants to change that. Geoffrey Cumming, a Canadian-born oil and gas businessman, donated AUD $250 million ($173.63 million) […]
SAN DIEGO, Aug. 31, 2022 /PRNewswire/ — The Third Option applauds the courage of organizations like the National Institute of Health and the Centers for Disease Control and Prevention (CDC) for utilizing Critical Race Theory […]
Lumakras, Amgen’s groundbreaking KRAS drug, was approved on data from an open-label, single-arm study suggesting, among other things, median progression-free survival of 6.8 months for patients with KRASG12C-mutated non-small cell lung cancer. Now, Amgen says […]
A microcap biotech player operating under a “going concern” alert is touting a tie-up with Bayer’s BlueRock, a high-profile outfit exploring the frontiers of cell therapy R&D. Sunnyvale, CA-based BioCardia says it nabbed a “sizable” […]
KFAR SABA, Israel and SANTA CLARA, Calif., Aug. 31, 2022 /PRNewswire/ — Sensifree LTD, a world innovator in advanced hemodynamic monitoring (“Sensifree”), received CE certificate for SentiCor-100® in compliance with the new EU MDR. The […]
CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ — ONO PHARMA USA, INC. (President and CEO, Kunihiko Ito, “OPUS”) announces its organization and leadership team expansion to advance its clinical development, research alliance, licensing activities, as well […]
Vilya, Inc. broke onto the BioForest biotech scene recently with $50M in Series A proceeds. The company will use cutting-edge computational techniques to develop innovative drugs for difficult-to-treat diseases. Vilya’s proprietary platform leverages sophisticated machine […]
© 2023 Biotech Networks, LLC
